Full title: Maternal influenza and birth outcomes: Systematic review of comparative studies

Short running title: Maternal influenza and birth outcomes

Abstract word count: 250

Manuscript word count: 3,994

Authors:

Ms. Deshayne B. FELL, PhD
Dr. David A. SAVITZ, PhD
Dr. Michael S. KRAMER, MD
Dr. Bradford D. GESSNER, MD
Dr. Mark A. KATZ, MD
Professor Marian KNIGHT, MD
Dr. Johannes M. LUTEIJN, PhD
Dr. Helen MARSHALL, MD
Dr. Niranjan BHAT, MD
Dr. Michael G. GRAVETT, MD
Ms. Becky SKIDMORE, MSc
Dr. Justin R. ORTIZ, MD

Affiliations:

1 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
Correspondence: Deshayne B. Fell, Better Outcomes Registry & Network (BORN), CHEO Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1 Canada. Email: deshayne.fell@mail.mcgill.ca

Author addresses:

Deshayne B. Fell
Better Outcomes Registry & Network (BORN)
CHEO Research Institute
401 Smyth Road
Ottawa, ON K1H 8L1 Canada
Tel: +1 613-737-7600 Ext. 6033
Email: deshayne.fell@mail.mcgill.ca

David A. Savitz
Department of Epidemiology, Obstetrics and Gynecology, Brown University
47 George Street
Providence, RI 02912 USA
Tel: +1 401-863-7408
Email: david_savitz@brown.edu

Michael S. Kramer
Department of Epidemiology, Biostatistics and Occupational Health, McGill University
4018 Ste-Catherine St W, Room K-116
Westmount, QC H3Z 1P2 Canada
Tel: +1 514 412 4400 ext. 22687
Email: michael.kramer@mcgill.ca

Bradford D. Gessner
Agence de Médecine Préventive
Mark A. Katz
Warburg St. 1 Apt. 2
Tel Aviv, Israel
Tel: +1 240 242 9209
Email: markakatz@gmail.com

Marian Knight
National Perinatal Epidemiology Unit (NPEU), University of Oxford
Old Road Campus
Oxford OX3 7LF United Kingdom
Tel: +44 1865 289706
Email: marian.knight@npeu.ox.ac.uk

Johannes M. Luteijn
Wolfson Institute of Preventive Medicine, Queen Mary University of London
Charterhouse Square
London EC1M 6BQ United Kingdom
Tel: +44 2078 826 286
Email: j.m.luteijn@qmul.ac.uk
Helen Marshall  
Vaccinology and Immunology Research Trials Unit, Discipline of Paediatrics  
Women's and Children's Hospital and University of Adelaide  
72 King William Rd  
North Adelaide, South Australia 5006 Australia  
Tel: +61 8 8161 8115  
Email: helen.marshall@adelaide.edu.au

Niranjan Bhat  
Vaccine Access and Delivery Program, PATH  
2201 Westlake Ave, Ste 200  
Seattle, WA 98121  
Tel: +1 206 285 3500  
Email: nbhat@path.org

Michael G. Gravett  
Department of Obstetrics and Gynaecology, University of Washington  
Mail Box: 356522  
1959 NE Pacific St.  
Seattle, WA 98195-6522 USA  
Email: gravettm@uw.edu

Becky Skidmore
Justin R. Ortiz
Initiative for Vaccine Research
World Health Organization
20, Avenue Appia
CH-1211 Geneva 27 Switzerland
Tel: +41 22 791 4224
Email: ortizj@who.int
ABSTRACT

Background: Although pregnant women are considered at high risk for severe influenza disease, comparative studies of maternal influenza and birth outcomes have not been comprehensively summarised.

Objective: To review comparative studies evaluating maternal influenza disease and birth outcomes.

Search strategy: We searched bibliographic databases from inception to December 2014.

Selection criteria: Studies of preterm birth, small-for-gestational-age (SGA) birth or fetal death, comparing women with and without clinical influenza illness or laboratory-confirmed influenza infection during pregnancy.

Data collection and analysis: Two reviewers independently abstracted data and assessed study quality.

Main results: Heterogeneity across 16 studies reporting preterm birth precluded meta-analysis. In a subgroup of the highest-quality studies, two reported significantly increased preterm birth (risk ratios [RR] from 2.4 to 4.0) following severe 2009 pandemic H1N1 (pH1N1) influenza illness, while those assessing mild-to-moderate pH1N1 or seasonal influenza found no association. Five studies of SGA birth showed no discernible patterns with respect to influenza disease severity (pooled odds ratio: 1.24; 95% CI: 0.96–1.59). Two fetal death studies were of sufficient quality and size to permit meaningful interpretation. Both reported an increased risk of fetal death following maternal pH1N1 disease (RR 1.9 for mild-to-moderate disease and 4.2 for severe disease).

Conclusions: Comparative studies of preterm birth, SGA birth and fetal death following maternal influenza disease are limited in number and quality. An association between severe pH1N1 disease and preterm birth and fetal death was reported by several studies; however these limited data do not permit firm conclusions on the magnitude of any association.
Keywords: fetal death, influenza, pregnancy, preterm birth, small-for-gestational-age birth, systematic review

Tweetable abstract: Comparative studies are limited in quality but suggest severe pandemic H1N1 influenza increases preterm birth risk.
Pregnant women are considered vulnerable to serious influenza disease and related complications. On the basis of evidence documenting excess influenza-related mortality in pregnant women during historical and recent pandemics\(^1\)–\(^3\) and higher rates of influenza-related morbidity requiring hospitalisation during seasonal epidemics,\(^4\)–\(^6\) many countries advise that women who are, or will be, pregnant during the influenza season be immunised with inactivated influenza vaccine.\(^7\)–\(^9\) Since 2012, the World Health Organization (WHO) has recommended that countries expanding or initiating influenza vaccination programs prioritize pregnant women for vaccine receipt.\(^10\) While the primary goal of these recommendations is to protect pregnant women from severe influenza disease, benefits of maternal immunisation have also been shown to extend to neonates through transfer of maternal antibodies, providing passive immunity against influenza virus infection.\(^11\)

The possibility that maternal influenza immunisation could be of additional value beyond prevention of maternal and neonatal influenza illness is of considerable public health interest.\(^12\)–\(^14\) In recent years, several observational studies and one secondary analysis of a randomised clinical trial have reported risk reductions for several adverse perinatal outcomes following influenza immunisation during pregnancy.\(^15\) The biologic plausibility of such findings depends on there being a direct or indirect adverse effect of maternal influenza disease on fetal health that is preventable via maternal immunisation. However, evidence on the effect of maternal influenza disease on birth outcomes is limited. The literature is dominated by descriptive case series reports that often lack complete information on birth outcomes,\(^16\) and existing systematic reviews have either predominantly synthesized evidence from descriptive studies of the 2009 H1N1 pandemic\(^16\)–\(^18\) or focused on teratogenic effects of early pregnancy influenza virus infection.\(^19\)
To address this evidence gap and inform expectations of possible benefits of maternal influenza vaccination on birth outcomes, the WHO initiated an evidence review of maternal influenza disease and adverse birth outcomes.\textsuperscript{20} The objective of this systematic review was to assess the risk of preterm birth, small-for-gestational-age (SGA) birth and fetal death among women with clinical influenza disease and/or laboratory-confirmed influenza virus infection during pregnancy, compared to women with no influenza during pregnancy.

METHODS

We developed a systematic review protocol (available on request) and prepared this manuscript following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.\textsuperscript{21}

Search strategy and study selection

This manuscript focuses on results from comparative studies; however, as part of a broader WHO evidence review,\textsuperscript{20} the literature searches and screening procedures pertain to the full evidence review. We performed electronic literature searches in MEDLINE, EMBASE, CINAHL and the Cochrane Library from inception to December 5, 2014. A medical librarian developed a sensitive search strategy utilising medical subject headings (e.g., “Influenza, Human”, “Pregnancy Complications”) and keywords (e.g., influenza, antenatal), and a second librarian peer-reviewed the strategy\textsuperscript{22} (full search strategy provided in Appendix S1). Following de-duplication, search records were uploaded into online software (Abstrak\textsuperscript{23}) and screened by two independent reviewers.

As part of the full WHO evidence review, we considered studies eligible for full-text review if they (i) employed comparative designs (i.e., cohort, case-control, cross-sectional), descriptive designs (i.e.,
ecologic, case series, case report) or were systematic reviews; (ii) examined women with clinical
influenza illness and/or laboratory-confirmed influenza virus infection during pregnancy; and (iii)
assessed any of the following primary outcomes: preterm birth (birth at less than 37 weeks of
gestation), SGA birth (birth weight below the 10th percentile for gestational age and sex), fetal death
(including miscarriage or stillbirth), or secondary outcomes: preterm birth utilising alternate gestational
age thresholds, mean gestational age, low birth weight (less than 2,500 grams), mean birth weight. The
preferred working definition for each outcome is shown in Table S1; however, individual studies were
not required to exactly meet these definitions to be included. Since we were not aware of any evidence
concerning the most potentially susceptible time window for fetal exposure to maternal influenza in
relation to our outcomes, we did not restrict the exposure definition to any particular gestational age
range.

We made the following exclusions: non-English language, editorials, commentaries, narrative reviews,
clinical practice guidelines, conference abstracts or literature not in peer-reviewed journals. The same
reviewers independently evaluated the full text of all studies identified in the first stage of screening and
resolved disagreements through consensus. Initially, we included influenza vaccination studies only if
they evaluated our review outcomes relative to maternal influenza illness. Following completion of the
initial screening process, however, we made a post hoc decision to include randomised controlled trials
(RCTs) of influenza vaccination during pregnancy in narrative syntheses (but not quantitative meta-
analyses), if a placebo control group was used. In addition to providing estimates of vaccine efficacy,
RCTs can help characterise the contribution of a vaccine-preventable pathogen, such as influenza, to a
range of clinical outcomes.24 Thus, we interpreted any differences in rates of adverse birth outcomes
between vaccinated and unvaccinated women as attributable to differences in the contribution of
influenza infection to the chain of events leading to the outcome.24
Data extraction and quality assessment

We developed a data collection form to extract information on study design and population, inclusion and exclusion criteria, definition and ascertainment of exposure and outcomes, method of gestational age measurement and confounding variables considered in any analyses. For binary outcomes, we extracted raw cell counts to reconstruct 2x2 tables and any measures of effect (i.e., relative risks [RR], hazards ratios [HR], odds ratios [OR], or risk differences [RD]) with 95% confidence intervals (CI). Where possible, we calculated crude effect estimates using raw data from the reconstructed 2x2 tables when they were not reported by the study.

Individual study quality was assessed by two reviewers using the Newcastle-Ottawa Scale for comparative observational studies or the Cochrane Collaboration risk of bias tool for RCTs. During our review, we developed a concern that ascertainment of clinical influenza disease and/or laboratory-confirmed influenza virus infection may have been influenced by concern about the pregnancy (for example, there may have been a different threshold for influenza diagnosis/hospitalisation among women with high-risk pregnancies or poor pregnancy outcome, than among women with low-risk pregnancies) resulting in differential misclassification of the exposure by study outcome. The impact of any such differential ascertainment would be expected to inflate the magnitude of effect estimates. To assess the risk of this potential differential exposure misclassification, which we denoted ‘diagnostic ascertainment bias’, we developed a rating system specifically for this review (Appendix S2) and rated each study as having low, medium, high, or very high risk of diagnostic bias based on the method of influenza ascertainment. Using an adapted GRADE framework, we rated the quality of evidence across studies for each primary outcome as high, moderate, low, or very low based on factors such as study design and limitations, inconsistency in study findings, and imprecision (Appendix S3).
Data synthesis and analysis

We summarised study characteristics in descriptive tables and Forest plots. To determine whether meta-analyses were appropriate, we considered clinical heterogeneity (i.e., measurement of influenza disease, clinical populations, outcome definitions and ascertainment), design heterogeneity (i.e., study design, analytical approach, extent of control for confounding factors), as well as statistical heterogeneity.\textsuperscript{29} The latter was quantified with the $I^2$ statistic, calculated using the natural log of the individual-study adjusted effect estimates (or crude estimates when adjustment was not performed by the original study) and 95% CIs in a random-effects model.\textsuperscript{30} The non-central $\chi^2$ method was used to compute a 95% CI around the $I^2$ statistic.\textsuperscript{31} Outcomes with $I^2$ values $<75\%$ were considered eligible for meta-analysis if clinical and design characteristics were not qualitatively judged as too variable. Conversely, all outcomes with $I^2$ values $\geq 75\%$ were considered inappropriate for meta-analysis, regardless of other considerations. In such cases, we attempted to explore possible sources of heterogeneity in post hoc analyses by evaluating outcomes within more homogeneous subgroups, defined according to methodological quality and characteristics of influenza. We used Stata SE 12.1 software (Stata-Corp LP, College Station, TX, USA) for all quantitative analyses.

RESULTS

Study selection

We identified 1,923 records through electronic literature searches, of which 101 were eligible for full-text review following title and abstract screening (Figure 1). Twenty-two articles were excluded after full-text review, leaving 79 studies in the broader WHO evidence review, including 56 descriptive studies and two systematic reviews of descriptive studies, not reported here. Among the comparative studies, we initially included 21 observational studies, but later excluded one\textsuperscript{32} after confirming that more
complete follow-up data on the same subjects had been reported in a subsequent publication. After completing our initial screening, we added one placebo-controlled RCT of influenza immunisation during pregnancy, bringing the final number of comparative studies to 21.11

Study characteristics and influenza ascertainment methods

Twelve studies were published in 2010 or later,11,33–43 five between 2000 and 2009,44–48 and the remainder prior to 2000.49–52 All of the observational studies originated from high-income countries, including half from the United States,34–36,38,40,43,44,46,50,51 while the RCT was carried out in South Africa.11 Thirteen studies reported findings from pre-2009 seasonal epidemics,38,41–52 five assessed influenza during the 2009 H1N1 pandemic,33,35–37,39 and remaining studies assessed a combination of seasonal influenza and 2009 pandemic H1N1 (pH1N1) influenza or studied influenza seasons post-2009.11 The majority of studies used either a retrospective33,35,36,38–40,42,44,46 or prospective37,41,43,47–51 cohort design (Table S2).

With the exception of the four prospective seroepidemiological studies, in which paired maternal sera collected in early gestation and postpartum were tested for influenza virus infection during pregnancy48–51 and the RCT with active surveillance,11 remaining studies ascertained influenza among pregnant women who presented for medical care with symptoms of clinical illness (Table S3). Four studies classified influenza status based on a self-reported measure of influenza-like illness collected either prospectively during pregnancy41,45 or by post-partum questionnaire.34,47 Among 12 studies that ascertained influenza illness diagnosed during health care visits, there was substantial variation in the type of clinical settings (i.e., ambulatory versus hospitalisations), gestational timing of when diagnoses were ascertained (i.e., during health care visits at any gestational age versus only during hospitalisations in which the delivery occurred) and use of laboratory testing for diagnostic confirmation. We
considered two studies to be at very high risk of diagnostic ascertainment bias owing to influenza ascertainment only at the time of the hospitalisation to give birth (i.e., coincident temporal diagnosis of influenza),\textsuperscript{38,44} seven studies were considered to be at high risk,\textsuperscript{33–35,42,46,47,52} and the remaining studies at medium or low risk (Table S3).

Preterm birth

Sixteen studies providing 17 estimates (one study provided separate estimates for two influenza seasons\textsuperscript{40}) assessed preterm birth (Figure 2; Table S4). We did not compute a pooled estimate, primarily due to high statistical heterogeneity ($I^2 = 98\%$; 95\% CI, 97–98); however, heterogeneity in influenza assessment methods was also a concern. Overall, individual-study ratio estimates of effect displayed in Figure 2 ranged widely (from 0.40 to 4.08). Among the 13 adjusted estimates provided, nine had confidence intervals that included the null value (with point estimates ranging from 0.82 to 1.27) and four reported statistically significant estimates greater than one (with point estimates ranging from 2.39 to 4.08). Results from the RCT of influenza vaccination are not displayed in the Forest plot, but the risk ratio for preterm birth computed from raw study data did not indicate any difference in preterm birth risk between treatment arms (Table S4). Using a modified GRADE framework,\textsuperscript{28} we rated the quality of evidence across the 16 studies as very low (Appendix S3).

Aside from one study of spontaneous preterm birth,\textsuperscript{41} baseline risks of preterm birth across the study populations ranged from 5.2\% to 11.5\% among women with no influenza disease (Figure 2), comparable to population estimates for preterm birth in high-income countries (Table S5). Among women with influenza disease, the range of preterm birth risks extended from 4.0\% to 25.8\%. Three of seven studies that ascertained only severe maternal influenza illness (i.e., all or most women were hospitalised, or
Selective laboratory testing was carried out only on women with symptoms of severe influenza disease) reported preterm birth risks in excess of 20% among women with influenza.\textsuperscript{33,35,38}

After subgrouping studies according to similarity in methods of influenza assessment, methodological quality and influenza season characteristics (Table S6), statistical heterogeneity remained high ($I^2 > 80\%$) within most subgroups. Among the studies considered to be of highest quality (i.e., a Newcastle-Ottawa Scale score $\geq 8$, risk of diagnostic ascertainment bias not rated as ‘very high’, and exposure not measured using a self-reported questionnaire), statistical heterogeneity was only marginally lower ($I^2 = 89\%; 95\% CI, 79–92$). The only subgroup in which heterogeneity was substantially reduced was that containing only studies of mild-to-moderate influenza illness ($I^2 = 0\%; 95\% CI, 0–53$; Table S6).

Among six studies considered of highest methodological quality, two of severe 2009 pH1N1 influenza disease reported a preterm birth risk of 24% among women with influenza,\textsuperscript{33,35} resulting in adjusted odds ratios of 2.4 and 4.0 (Figure S1; Table S6). Three other 2009 pH1N1 studies based on a wider range of illness severity reported no significantly elevated risk of preterm birth (adjusted odds ratios from 1.03 to 1.27).\textsuperscript{36,39,40} In the two highest-quality studies from seasonal epidemic years, no association was observed between influenza and preterm birth, whether based on hospitalisation for influenza disease\textsuperscript{42} or broader ascertainment criteria.\textsuperscript{40} In the RCT of influenza vaccination (Table S4), there was no difference in the proportions of preterm birth in the two arms despite a 50% reduction in maternal influenza disease in the active treatment group.\textsuperscript{11}

**SGA birth**

Five studies providing six estimates assessed SGA birth.\textsuperscript{36,37,40,42,48} Three studies defined SGA birth as sex-specific birth weight $<10^{th}$ percentile, each relative to different reference standards,\textsuperscript{36,40,42} another used
birth weight <10th percentile determined from the distribution within the study population, and the fifth examined intrauterine growth restriction but provided no specific definition (Table S7). Baseline risks of SGA birth ranged from 3.9% to 14.1% in women with no influenza disease during pregnancy, and from 2.8% to 15.3% among women who had influenza disease. Aside from differences in definitions of SGA birth, quality was a lesser concern in this group of studies than it was for preterm birth — most of the point estimates originated from studies with a Newcastle-Ottawa Score of 8 or 9 and most studies were considered to have a medium or low risk of diagnostic ascertainment bias. Using the modified GRADE framework, we rated the quality of evidence across the studies as low (Appendix S3).

Among the five adjusted ratio estimates provided, three had confidence intervals that included the null value (with point estimates ranging from 0.71 to 1.14), while two reported statistically significant estimates greater than one (with point estimates of 1.59 and 1.66). Since the $I^2$ statistic was 43% (95% CI, 0–76) and clinical heterogeneity was not considered prohibitively high, we computed a pooled OR of 1.24 (95% CI, 0.96–1.59; Figure 3). The number of studies examining this outcome was insufficient for subgroup analyses; however, we noted that both studies reporting an association between SGA birth and maternal influenza were from non-pandemic influenza seasons, while none of the three studies from the 2009 H1N1 pandemic found any association. The only study of severe influenza disease reported an increased risk of SGA birth (adjusted OR 1.66; 95% CI, 1.11–2.49). Another found no association with SGA birth in a primary analysis, but in a secondary analysis limited to women with severe influenza disease, reported an adjusted OR of 2.35 (95% CI, 1.03–5.36).

Fetal death
Fetal death was reported in 10 publications (Figure 4; Table S8); however, meta-analysis of results across studies was not possible because of high variability in fetal death definitions. Several studies used specific terminology to refer to mortality outcomes, such as spontaneous abortion or stillbirth, but did not specify the gestational age ranges underlying these definitions, while three others provided no clarifying information. Only three of the studies specified a definition of fetal death. The GRADE quality of evidence rating across the studies was very low (Appendix S3).

Inadequate numbers of mortality events in most of these studies also seriously limited meaningful interpretation of results. Although there was a combined total of 103,902 fetal deaths reported from over 17 million participants, most (103,326/103,902; 99.4%) were reported from one very large study conducted in the United States across 10 influenza seasons using a hospitalisation database. Despite the large sample size, we considered this study to be at very high risk of diagnostic ascertainment bias as influenza was ascertained only at the time of hospitalisation to give birth. The two highest-quality studies were conducted during the 2009 pandemic and ascertained influenza disease occurring at any point during pregnancy. One reflected only severe maternal illness requiring hospitalisation (adjusted OR 4.2; 95% CI, 1.4–12.4), while the other reflected mild-to-moderate maternal influenza illness severity and reported an adjusted hazard ratio of 1.91 (95% CI, 1.07–3.41). In the South African RCT of influenza vaccination (not displayed in Figure 4; see Table S8), the number of miscarriages between 20 and 27 weeks and stillbirths ≥28 weeks was too small for meaningful interpretation (8 miscarriages and 24 stillbirths among non-HIV infected women in total).

Results for secondary outcomes are provided in the Supporting Information (Appendix S4 and Tables S9 through S13).
DISCUSSION

Main findings

Our systematic review has found that comparative studies of adverse birth outcomes following maternal influenza disease are limited in quantity and have produced inconsistent findings. The overall quality of evidence across studies was considered low to very low, due to the limited number of studies (particularly for SGA birth and fetal death), inconsistency of results and concerns about potential differential ascertainment of influenza by pregnancy outcome. Because of these limitations, firm conclusions are difficult to draw, although several studies suggest that severe maternal disease due to 2009 pH1N1 influenza is associated with preterm birth. We did not find evidence for an association with mild-to-moderate 2009 pH1N1 influenza, nor with seasonal influenza of any severity. Drawing any overall conclusions on the risk of fetal death following maternal influenza is challenging due to insufficient mortality events in most studies and inconsistent study definitions of fetal death. The two highest-quality studies both reported significantly increased risks of fetal death following maternal 2009 pH1N1 influenza illness, but high-quality evidence from seasonal influenza time periods is lacking.

Strengths and limitations

Strengths of our review include the comprehensive literature search strategy, focus on comparative studies and thorough assessment of the quality of the evidence. The most important limitation of the primary studies we reviewed relates to measurement and ascertainment of influenza. A particular concern was that seeking medical attention for influenza illness, being selected for microbiological confirmation or hospitalised for influenza could have been motivated by concerns about the pregnancy, potentially leading to differential misclassification of the exposure by study outcome. The impact of any such differential ascertainment would be expected to exaggerate effect sizes, making influenza appear more strongly associated with adverse outcomes, though the potential extent of any
such bias is unclear. There was also high potential for non-differential misclassification of influenza status in many studies (e.g., if influenza illness was only ascertained in hospitalised cases or at a singular time point in gestation), which would tend to bias point estimates closer to the null value. With the exception of SGA birth, we were unable to pool data across studies due to high heterogeneity. We relied on the $I^2$ statistic to assess statistical heterogeneity; however, there were wide confidence intervals around many $I^2$ values resulting from the small number of studies. Many studies reported odds ratios rather than risk or hazard ratios, which may have inflated the apparent magnitude of any association in studies where rates of study outcomes exceeded 10%. As noted by other systematic reviews, definitions of perinatal outcomes were heterogeneous and poorly reported. Methods of gestational age determination were also poorly reported despite being integral to defining outcomes such as preterm birth and fetal mortality.

Interpretation

RCTs of influenza vaccination during pregnancy provide complimentary evidence relating influenza disease and adverse birth outcomes, which is useful to consider in this context given the low quality, mixed evidence from epidemiologic studies. Two such trials have been published, both of which demonstrated efficacy in preventing influenza disease in pregnant women. Results from the trials with respect to birth outcomes, however, were dissimilar. While the trial conducted in Bangladesh found higher mean birth weight and a lower percentage of SGA infants among a subset of infants born during the influenza season to influenza-vaccinated women, the trial from South Africa did not detect any differences in preterm birth, low birth weight or median birth weight between treatment groups overall, or when assessed by maternal influenza infection status. Whether these divergent findings resulted from local differences in influenza season characteristics, vaccine components or comparators
(active control\textsuperscript{59,60} versus placebo control\textsuperscript{11}) is unclear. Forthcoming evidence from two additional RCTs\textsuperscript{62,63} may help clarify currently available results.

Most previous systematic reviews of influenza disease during pregnancy and birth outcomes have focused on descriptive studies from the 2009 H1N1 pandemic\textsuperscript{16–18} or on teratogenic effects of early pregnancy influenza virus infection.\textsuperscript{19} One other recent review included both descriptive and comparative studies, but provided limited synthesis of comparative findings for influenza disease and birth outcomes.\textsuperscript{64} Similar to our observations, most descriptive studies that support an association between pH1N1 influenza illness and adverse birth outcomes were among severely ill women,\textsuperscript{16–18,64} while the few case series not reaching this conclusion described a broader population of pregnant women with milder clinical disease.\textsuperscript{65,66} It remains unclear whether the associations with adverse birth outcomes found by some comparative studies from the 2009 pandemic reflect an increased biological susceptibility of pregnant women to the 2009 pH1N1 virus, possibly from lower levels of pre-existing immunity or differences in virulence,\textsuperscript{67} or whether enhanced surveillance and potential for disproportionate diagnosis of pregnant women during that time period played a role.\textsuperscript{36,65} Since the epidemiological characteristics of the 2009 influenza pandemic were different from surrounding seasonal epidemics,\textsuperscript{68} a distinctive impact of the 2009 pH1N1 virus on pregnant women is plausible, but firm conclusion is limited by the small number of studies and the low quality of the comparative evidence.

Although sequelae from infection with some viral pathogens in pregnancy are well understood (e.g., congenital cytomegalovirus, rubella, varicella),\textsuperscript{69,70} potential pathogenic effects of influenza viruses on the fetus are not. Since the influenza virus is rarely transmitted across the placenta,\textsuperscript{48,71} influenza virus infection is more likely to be associated with adverse birth outcomes through other mechanisms such as
maternal fever and inflammation.\textsuperscript{71–73} Immunological responses, such as elevated pro-inflammatory cytokine levels,\textsuperscript{74} can also influence placental function\textsuperscript{75,76} and are recognized as an important pathway to preterm birth.\textsuperscript{77,78} Secondary pneumonia was also identified as a contributing factor for excess fetal deaths during the influenza pandemic of 1918–1919.\textsuperscript{1} More recently, women hospitalised with 2009 pH1N1 influenza illness had significantly increased risk of preterm delivery if they developed secondary pneumonia compared with those who did not develop pneumonia (71\% versus 27\%).\textsuperscript{33} In the case of an outcome such as preterm birth, which is defined only by the timing of birth, not by a clinical phenotype,\textsuperscript{79,80} it is pertinent to note that biological mechanisms can be implicated not only for spontaneous preterm birth, but also for iatrogenic preterm birth, since the latter is often motivated by poor maternal condition.\textsuperscript{33,81}

CONCLUSIONS

High-quality data on the effect of maternal influenza disease on birth outcomes are necessary for informing public health policies for pregnant women and for clarifying expectations for improved perinatal outcomes following maternal influenza immunisation. Yet, our systematic review has found the evidence base from comparative studies on this subject to be limited. While a small subgroup of higher-quality studies found that severe pH1N1 influenza disease during pregnancy increased the risk of preterm birth and fetal death, there was little evidence that mild 2009 pH1N1 influenza, seasonal influenza disease of any severity, or subclinical infection in pregnant women was associated with the outcomes assessed in this review. A number of substantive gaps in the primary literature remain including insufficient evidence on seasonal influenza disease, gestational timing of influenza disease, and from low-resource settings.
Disclosure of interests: Justin R. Ortiz works for the World Health Organization. The remaining authors report no conflicts of interest.

Contribution to authorship: DBF developed the study protocol, screened articles for inclusion, extracted data from the included studies, analysed the data, interpreted the results and drafted the manuscript. DAS, MSK, JRO, and BDG developed the study protocol, interpreted the results, and critically reviewed all drafts of the manuscript. MAK screened articles for inclusion, interpreted the results, and critically reviewed all drafts of the manuscript. MK, JML, HM, NB, and MGG interpreted the results, and critically reviewed all drafts of the manuscript. BS developed the search strategy, conducted the literature search, and critically reviewed all drafts of the manuscript. All authors have seen and approved the final version of this manuscript.

Details of ethical approval: No ethical approval was required for this review as all data were already published in peer-reviewed journals.

Funding: World Health Organization.

Disclaimer: The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the World Health Organization.

Acknowledgements: The authors thank Helena Bleeker, Corinne Riddell, Elizabeth Darling, and Jeanene Johnson for their assistance with data extraction and/or quality assessment, and Jeanette Jones for editorial assistance. The authors would also like to acknowledge Margaret Sampson, MLIS, PhD, AHIP, Medical Librarian at the Children’s Hospital of Eastern Ontario, for peer-reviewing the search strategy.
Additional Supporting Information may be found in the online version of this article:

Appendix S1. Full search strategy with results
Appendix S2. Risk of diagnostic ascertainment bias assessment
Appendix S3. Assessment of primary study outcomes using adaptation of Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for assessing the quality of the evidence across studies
Appendix S4. Secondary outcomes
Supplementary Tables. Table S1 to Table S13
Figure S1. Forest plot of highest quality studies reporting preterm birth by influenza season and severity of maternal illness
REFERENCES

1. Harris J. Influenza occurring in pregnant women. *J Am Med Assoc.* 1919;72(14):978-980.

2. FREEMAN DW, BARNO A. Deaths from Asian influenza associated with pregnancy. *Am J Obstet Gynecol.* 1959;78:1172-1175.

3. Siston AM, Rasmussen S a, Honein M a, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. *JAMA.* 2010;303(15):1517-1525. doi:10.1001/jama.2010.479.

4. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *CMAJ.* 2007;176(4):463-468. doi:10.1503/cmaj.061435.

5. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of Influenza on Acute Cardiopulmonary Hospitalizations in Pregnant Women. *Am J Epidemiol.* 1998;148(11):1094-1102. doi:10.1093/oxfordjournals.aje.a009587.

6. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. *BMJ.* 2013;347(August):f5061. doi:10.1136/bmj.f5061.

7. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. *MMWR Morb Mortal Wkly Rep.* 2014;63(32):691-697.

8. Immunisation JC on V and. JCVI statement on the annual influenza vaccination programme – extension of the programme to children. 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224775/JCVI-statement-on-the-annual-influenza-vaccination-programme-25-July-2012.pdf.

9. National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2011-2012. *Canada Commun Dis Rep.* 2011;37:1-55.

10. World Health Organization. Vaccines against influenza WHO position paper - November 2012. *Wkly Epidemiol Rec.* 2012;47:461-476.

11. Madhi S a., Cutland CL, Kuwanda L, et al. Influenza Vaccination of Pregnant Women and Protection of Their Infants. *N Engl J Med.* 2014;371(10):918-931. doi:10.1056/NEJMoa1401480.

12. Steinhoff MC, MacDonald N, Pfeifer D, Muglia LJ. Influenza vaccine in pregnancy: policy and research strategies. *Lancet.* 2014;383(9929):1611-1613. doi:10.1016/S0140-6736(14)60583-3.
13. Ortiz JR, Englund J a, Neuzil KM. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. *Vaccine*. 2011;29(27):4439-4452. doi:10.1016/j.vaccine.2011.04.048.

14. Savitz DA, Fell DB, Ortiz JR, Bhat N. Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. *Vaccine*. 2015. doi:10.1016/j.vaccine.2015.08.041.

15. Fell DB, Platt RW, Lanes A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. *BJOG*. 2015;122(1):17-26. doi:10.1111/1471-0528.12977.

16. Mosby LG, Rasmussen S a, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. *Am J Obstet Gynecol*. 2011;205(1):10-18. doi:10.1016/j.ajog.2010.12.033.

17. Liu S-L, Wang J, Yang X-H, et al. Pandemic influenza A(H1N1) 2009 virus in pregnancy. *Rev Med Virol*. 2013;23(1):3-14. doi:10.1002/rmv.1712.

18. Bhalerao-Gandhi A, Chhabra P, Arya S, Zimmerman JM. Influenza and pregnancy: a review of the literature from India. *Infect Dis Obstet Gynecol*. 2015;2015:867587. doi:10.1155/2015/867587.

19. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. *Hum Reprod*. 2014;29(4):809-823. doi:10.1093/humrep/det455.

20. World Health Organization. WHO Taskforce to Evaluate Influenza Data to Inform Vaccine Impact and Economic Modelling. 2014. http://www.who.int/entity/immunization/sage/meetings/2015/april/1_Interim_Report_WHO_Initiative_Vaccine_Research_24March_2015_execSAGE.pdf?ua=1.

21. Moher D, Liberati a., Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Bmj*. 2009;339(jul21 1):b2535-b2535. doi:10.1136/bmj.b2535.

22. McGowan J, Sampson M, Lefebvre C. An Evidence Based Checklist for the Peer Review of Electronic Search Strategies (PRESS EBC). *Evid Based Libr Inf Pract*. 2010;5(1):149-154.

23. Wallace BC, Small K, Brodley CE, Lau J, Trikalinos T a. Deploying an interactive machine learning system in an evidence-based practice center. *Proc 2nd ACM SIGHIT Symp Int Heal informatics - IHI ’12*. 2012:819. doi:10.1145/2110363.2110464.

24. Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden. *Lancet*. 2014;383(9930):1762-1770. doi:10.1016/S0140-6736(13)61682-7.

25. Wells GA, Shea B O’Connell D, Peterson J, Welch V, Losos M TP. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses.
26. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.

27. Guyatt G, Oxman AD, Akl E, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026.

28. Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst Rev*. 2013;2:71. doi:10.1186/2046-4053-2-71.

29. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.

30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557.

31. Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ*. 2007;335(7626):914-916. doi:10.1136/bmj.39343.408449.80.

32. Yates L, Pierce M, Stephens S, et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. *Health Technol Assess*. 2010;14(34):109-182. doi:10.3310/hta14340-02.

33. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. *BMJ*. 2011;342(jun14 2):d3214. doi:10.1136/bmj.d3214.

34. Ahrens K, Louik C, Kerr S, Mitchell A, Werler MM. Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small for gestational age birth. *Paediatr Perinat Epidemiol*. 2014;28(6):498-509. doi:10.1111/ppe.12152.

35. Doyle TJ, Goodin K, Hamilton JJ. Maternal and neonatal outcomes among pregnant women with 2009 pandemic influenza A(H1N1) illness in Florida, 2009-2010: a population-based cohort study. *PLoS One*. 2013;8(10):e79040. doi:10.1371/journal.pone.0079040.

36. Naresh A, Fisher BM, Hoppe KK, et al. A multicenter cohort study of pregnancy outcomes among women with laboratory-confirmed H1N1 influenza. *J Perinatol*. 2013;33(12):939-943. doi:10.1038/jp.2013.110.

37. Nieto-Pascual L, Arjona-Berral JE, Marín-Martin EM, Muñoz-Gomariz E, Ilich I, Castelo-Branco C. Early prophylactic treatment in pregnant women during the 2009-2010 H1N1 pandemic: obstetric and neonatal outcomes. *J Obstet Gynaecol*. 2013;33(2):128-134. doi:10.3109/01443615.2012.740526.
38. Martin A, Cox S, Jamieson DJ, Whiteman MK, Kulkarni A, Tepper NK. Respiratory illness hospitalizations among pregnant women during influenza season, 1998-2008. *Matern Child Health J*. 2013;17(7):1325-1331. doi:10.1007/s10995-012-1135-3.

39. Häberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *N Engl J Med*. 2013;368(4):333-340. doi:10.1056/NEJMoa1207210.

40. Hansen C, Desai S, Bredfeldt C, et al. A large, population-based study of 2009 pandemic Influenza A virus subtype H1N1 infection diagnosis during pregnancy and outcomes for mothers and neonates. *J Infect Dis*. 2012;206(8):1260-1268. doi:10.1093/infdis/jis488.

41. Morken N-H, Gunnes N, Magnus P, Jacobsson B. Risk of spontaneous preterm delivery in a low-risk population: the impact of maternal febrile episodes, urinary tract infection, pneumonia and ear-nose-throat infections. *Eur J Obstet Gynecol Reprod Biol*. 2011;159(2):310-314. doi:10.1016/j.ejogrb.2011.08.006.

42. McNeil S a, Dodds L a, Fell DB, et al. Effect of respiratory hospitalization during pregnancy on infant outcomes. *Am J Obstet Gynecol*. 2011;204(6 Suppl 1):S54-S57. doi:10.1016/j.ajog.2011.04.031.

43. Rogers VL, Sheffield JS, Roberts SW, et al. Presentation of seasonal influenza A in pregnancy: 2003-2004 influenza season. *Obstet Gynecol*. 2010;115(5):924-929. doi:10.1097/AOG.0b013e3181da0c5e.

44. Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. Hospitalizations with respiratory illness among pregnant women during influenza season. *Obstet Gynecol*. 2006;107(6):1315-1322. doi:10.1097/01.AOG.0000218702.92005.bb.

45. Acs N, Bánhidy F, Puhó E, Czeizel AE. Pregnancy complications and delivery outcomes of pregnant women with influenza. *J Matern Fetal Neonatal Med*. 2006;19(3):135-140. doi:10.1080/14767050500381180.

46. Hartert T V, Neuzil KM, Shintani AK, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. *Am J Obstet Gynecol*. 2003;189(6):1705-1712. doi:10.1016/S0002-9378(03)00857-3.

47. Tuyishime J-D, De Wals P, Moutquin J-M, Frost E. Influenza-like illness during pregnancy: results from a study in the eastern townships, Province of Quebec. *J Obstet Gynaecol Can*. 2003;25(12):1020-1025.

48. Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. *BJOG*. 2000;107(10):1282-1289.

49. Griffiths PD, Ronalds CJ, Heath RB. A prospective study of influenza infections during pregnancy. *J Epidemiol Community Health*. 1980;34(2):124-128.
50. Korones SB, Todaro J, Roane JA, Sever JL. Maternal virus infection after the first trimester of pregnancy and status of offspring to 4 years of age in a predominantly Negro population. *J Pediatr*. 1970;77(2):245-251.

51. Wilson MG, Stein AM. Teratogenic effects of asian influenza. *JAMA*. 1969;210(2):336-337.

52. Stanwell-Smith R, Parker AM, Chakraverty P, Soltanpoor N, Simpson CN. Possible association of influenza A with fetal loss: investigation of a cluster of spontaneous abortions and stillbirths. *Commun Dis Rep CDR Rev*. 1994;4(3):R28-R32.

53. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. *N Engl J Med*. 2014;370(23):2211-2218. doi:10.1056/NEJMra1213566.

54. Von Hippel PT. The heterogeneity statistic I (2) can be biased in small meta-analyses. *BMC Med Res Methodol*. 2015;15(1):35. doi:10.1186/s12874-015-0024-z.

55. Cummings P. The relative merits of risk ratios and odds ratios. *Arch Pediatr Adolesc Med*. 2009;163(5):438-445. doi:10.1001/archpediatrics.2009.31.

56. McNutt L-A, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am J Epidemiol*. 2003;157(10):940-943.

57. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. *Jama*. 2014;311(15):1536-1546. doi:10.1001/jama.2014.2269.

58. Aminu M, Unkels R, Mdegela M, Utz B, Adaji S, van den Broek N. Causes of and factors associated with stillbirth in low- and middle-income countries: a systematic literature review. *BJOG*. 2014;121 Suppl :141-153. doi:10.1111/1471-0528.12995.

59. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. *N Engl J Med*. 2008;359(15):1555-1564. doi:10.1056/NEJMoa0708630.

60. Steinhoff MC, Omer SB, Roy E, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. *CMAJ*. 2012;184(6):645-653. doi:10.1503/cmaj.110754.

61. Simões E a. F, Cutland C, Carosone-Link P, et al. 1899. Lack of efficacy of trivalent influenza vaccination of HIV Negative pregnant women against adverse fetal outcomes: A Randomized Clinical Trial. In: *IDSA*. San Diego, CA; 2015.

62. Tielsch JM, Steinhoff M, Katz J, et al. Designs of two randomized, community-based trials to assess the impact of influenza immunization during pregnancy on respiratory illness among pregnant women and their infants and reproductive outcomes in rural Nepal. *BMC Pregnancy Childbirth*. 2015;15(1):1-10. doi:10.1186/s12884-015-0470-y.
699. Omer SB, Richards JL, Madhi SA, et al. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations. Vaccine. 2015;33(32):3801-3812. doi:10.1016/j vaccine.2015.05.077.

702. Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand. 2015. doi:10.1111/aogs.12680.

704. Malinowski AK, McGeer A, Robertson J, et al. H1N1 in pregnancy: a tertiary care centre experience. J Obstet Gynaecol Can. 2011;33(7):698-704.

706. Gérardin P, El Amrani R, Cyrille B, et al. Low clinical burden of 2009 pandemic influenza A (H1N1) infection during pregnancy on the island of La Réunion. PLoS One. 2010;5(5):e10896. doi:10.1371/journal.pone.0010896.

709. Steinhoff MC. Epidemiology and Prevention of Influenza. In: Nelson K, Masters Williams C, eds. Infectious Disease Epidemiology. Theory and Practice. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers; 2007:577-600.

712. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr. 2010;2:RRN1153. doi:10.1371/currents.RRN1153.

715. Yinon Y, Farine D, Yudin MH, et al. Cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2010;32(4):348-354.

717. Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013;146(5):R151-R162. doi:10.1530/REP-13-0232.

719. Steinhoff MC, MacDonald NE. Influenza pandemics--pregnancy, pathogenesis, and perinatal outcomes. JAMA. 2012;308(2):184-185. doi:10.1001/jama.2012.7911.

721. Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006;76(7):507-516. doi:10.1002/bdra.20277.

723. Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal Hyperthermia and the Risk for Neural Tube Defects in Offspring. Epidemiology. 2005;16(2):216-219. doi:10.1097/01.ede.0000152903.55579.15.

726. Bradley-Stewart A, Jolly L, Adamson W, et al. Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09. J Clin Virol. 2013;58(1):100-107. doi:10.1016/j.jcv.2013.05.011.

728. Steinhoff MC, Omer SB. A review of fetal and infant protection associated with antenatal influenza immunization. Am J Obstet Gynecol. 2012;207(3 Suppl):S21-S27. doi:10.1016/j.ajog.2012.06.071.
76. Lieberman RW, Bagdasarian N, Thomas D, Van De Ven C. Seasonal influenza A (H1N1) infection in early pregnancy and second trimester fetal demise. Emerg Infect Dis. 2011;17(1):107-109. doi:10.3201/eid1701.091895.

77. Gravett MG, Rubens CE, Nunes TM. Global report on preterm birth and stillbirth (2 of 7): discovery science. BMC Pregnancy Childbirth. 2010;10 Suppl 1(Suppl 1):S2. doi:10.1186/1471-2393-10-S1-S2.

78. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010;362(6):529-535. doi:10.1056/NEJMra0904308.

79. Kramer MS, Papageorghiou A, Culhane J, et al. Challenges in defining and classifying the preterm birth syndrome. Am J Obstet Gynecol. 2012;206(2):108-112. doi:10.1016/j.ajog.2011.10.864.

80. Barros FC, Papageorghiou AT, Victora CG, et al. The Distribution of Clinical Phenotypes of Preterm Birth Syndrome. JAMA Pediatr. 2015;169(3):220. doi:10.1001/jamapediatrics.2014.3040.

81. Savitz D a, Dole N, Herring AH, et al. Should spontaneous and medically indicated preterm births be separated for studying aetiology? Paediatr Perinat Epidemiol. 2005;19(2):97-105. doi:10.1111/j.1365-3016.2005.00637.x.

32
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing study selection process.

- Descriptive studies and systematic reviews were screened as part of the overall evidence review, but are not reported in this publication.

- Yates et al., 2010\textsuperscript{32} and Pierce et al., 2011\textsuperscript{33} used the same study population, the former representing an earlier version of the study, published before full follow-up had been completed. Only the Pierce et al. study\textsuperscript{33} is reported in this review.

- Subsequent to the original screening, a placebo-controlled randomised clinical trial (RCT) of influenza immunisation during pregnancy was included.\textsuperscript{11}

Figure 2. Forest plot of individual study results for association between influenza illness during pregnancy and preterm birth. Small, black diamond markers indicate individual study point, with corresponding 95% confidence intervals (CIs) represented by horizontal bars.

- Risk of preterm birth per 100 women classified as having (exposed) or not having (unexposed) influenza illness/infection during pregnancy.

- For observational studies, ‘✓’ indicates a Newcastle Ottawa Score ≥8, risk of diagnostic ascertainment bias not rated as ‘very high’, and exposure not measured using self-reported questionnaire.

- Crude estimates were used in place of adjusted estimates when the latter were not provided.

- Hansen, 2012\textsuperscript{40} is shown twice: one estimate for 2009 A (pH1N1) and one for 2008–2009 influenza season.

- Håberg, 2013\textsuperscript{39} did not provide the risk of preterm birth by exposure group. Overall risk in the study population was 5.4 per 100 singleton live births.

- Morken, 2011\textsuperscript{41} studied spontaneous preterm birth only.
Baseline risk of preterm birth in the study population was not provided.  

Figure 3. Forest plot of individual study results for association between influenza illness during pregnancy and small-for-gestational-age (SGA) birth. Small, black diamond markers indicate individual study point, with corresponding 95% confidence intervals (CIs) represented by horizontal bars.

Risk of SGA birth per 100 women classified as having (exposed) or not having (unexposed) influenza illness/infection during pregnancy.

For observational studies, ‘✓’ indicates a Newcastle Ottawa Score ≥8, risk of diagnostic ascertainment bias not rated as ‘very high’, and exposure not measured using self-reported questionnaire.

Crude estimates were used in place of adjusted estimates when the latter were not provided.

Figure 4. Forest plot of individual study results for association between influenza illness during pregnancy and fetal death. Small, black diamond markers indicate individual study point, with corresponding 95% confidence intervals (CIs) represented by horizontal bars.

Risk of fetal death birth per 1,000 women classified as having (exposed) or not having (unexposed) influenza illness/infection during pregnancy.

For observational studies, ‘✓’ indicates a Newcastle Ottawa Score ≥8, risk of diagnostic ascertainment bias not rated as ‘very high’, and exposure not measured using self-reported questionnaire.

Crude estimates were used in place of adjusted estimates when the latter were not provided.
d Nieto-Pascual, 2013\textsuperscript{37} is shown twice: one estimate for abortion (RR: 0.40) and one for intrauterine fetal death (RR: 1.19)

e Not further defined.

f Håberg, 2013\textsuperscript{39} did not provide the risk of fetal death by exposure group. Overall risk in the study population was 4.3 fetal deaths per 1,000 pregnancies.

g Based on ICD-9 diagnostic codes.

h Risk of fetal death cannot be calculated because this was a case-control study.

i Irving, 2000\textsuperscript{48} had no fetal death events among unexposed women and only one event among exposed women; therefore an effect estimate could not be computed.